118 related articles for article (PubMed ID: 21269981)
41. TUM2-PK (pyruvate kinase type tumor M2), CA19-9 and CEA in patients with benign, malignant and metastasizing pancreatic lesions.
Cerwenka H; Aigner R; Bacher H; Werkgartner G; el-Shabrawi A; Quehenberger F; Mischinger HJ
Anticancer Res; 1999; 19(1B):849-51. PubMed ID: 10216504
[TBL] [Abstract][Full Text] [Related]
42. [Evaluation of combined determinations of Epstein-Barr virus antibodies for nasopharyngeal carcinoma assessed with receiver operating characteristic curve based on logistic regression].
Cai YL; Zheng YM; Cheng JR; Li J; Mo YK; Zhong QY
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2009 Oct; 23(5):384-7. PubMed ID: 20387494
[TBL] [Abstract][Full Text] [Related]
43. Clinical significance of cathepsin E in pancreatic juice in the diagnosis of pancreatic ductal adenocarcinoma.
Uno K; Azuma T; Nakajima M; Yasuda K; Hayakumo T; Mukai H; Sakai T; Kawai K
J Gastroenterol Hepatol; 2000 Nov; 15(11):1333-8. PubMed ID: 11129230
[TBL] [Abstract][Full Text] [Related]
44. Clinical significance of the measurements of serum matrix metalloproteinase-9 and its inhibitor (tissue inhibitor of metalloproteinase-1) in patients with pancreatic cancer: metalloproteinase-9 as an independent prognostic factor.
Mroczko B; Lukaszewicz-Zajac M; Wereszczynska-Siemiatkowska U; Groblewska M; Gryko M; Kedra B; Jurkowska G; Szmitkowski M
Pancreas; 2009 Aug; 38(6):613-8. PubMed ID: 19629003
[TBL] [Abstract][Full Text] [Related]
45. Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection.
O'Brien DP; Sandanayake NS; Jenkinson C; Gentry-Maharaj A; Apostolidou S; Fourkala EO; Camuzeaux S; Blyuss O; Gunu R; Dawnay A; Zaikin A; Smith RC; Jacobs IJ; Menon U; Costello E; Pereira SP; Timms JF
Clin Cancer Res; 2015 Feb; 21(3):622-31. PubMed ID: 24938522
[TBL] [Abstract][Full Text] [Related]
46. Pancreatic cancer serum biomarker PC-594: Diagnostic performance and comparison to CA19-9.
Ritchie SA; Chitou B; Zheng Q; Jayasinghe D; Jin W; Mochizuki A; Goodenowe DB
World J Gastroenterol; 2015 Jun; 21(21):6604-12. PubMed ID: 26074698
[TBL] [Abstract][Full Text] [Related]
47. Evaluation of circulating ADH and MIC-1 as diagnostic markers in Egyptian patients with pancreatic cancer.
Mohamed AA; Soliman H; Ismail M; Ziada D; Farid TM; Aref AM; Al Daly ME; Abd Elmageed ZY
Pancreatology; 2015; 15(1):34-9. PubMed ID: 25464937
[TBL] [Abstract][Full Text] [Related]
48. Correlations between serum trypsinogen-2 and pancreatic cancer.
Cao J; Xia C; Cui T; Guo H; Li H; Ren Y; Wang S
Hepatogastroenterology; 2015; 62(138):435-40. PubMed ID: 25916077
[TBL] [Abstract][Full Text] [Related]
49. Comparative study of CA242 and CA19-9 for the diagnosis of pancreatic cancer.
Kawa S; Tokoo M; Hasebe O; Hayashi K; Imai H; Oguchi H; Kiyosawa K; Furuta S; Homma T
Br J Cancer; 1994 Sep; 70(3):481-6. PubMed ID: 8080734
[TBL] [Abstract][Full Text] [Related]
50. Evaluation of matrix metalloproteinase 7 in plasma and pancreatic juice as a biomarker for pancreatic cancer.
Kuhlmann KF; van Till JW; Boermeester MA; de Reuver PR; Tzvetanova ID; Offerhaus GJ; Ten Kate FJ; Busch OR; van Gulik TM; Gouma DJ; Crawford HC
Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):886-91. PubMed ID: 17507610
[TBL] [Abstract][Full Text] [Related]
51. [Expression and clinical significance of plasma small RNA in patients with pancreatic cancer].
Pan W; Tang W; Yuan W; Yu Q; Zuo W; Xu C; Ma J
Zhonghua Zhong Liu Za Zhi; 2014 May; 36(5):351-4. PubMed ID: 25030590
[TBL] [Abstract][Full Text] [Related]
52. Serum CEACAM1 Level Is Associated with Diagnosis and Prognosis in Patients with Osteosarcoma.
Yu H; Yu J; Ren Y; Yang Y; Xiao X
PLoS One; 2016; 11(4):e0153601. PubMed ID: 27074014
[TBL] [Abstract][Full Text] [Related]
53. Clinical and experimental studies regarding the expression and diagnostic value of carcinoembryonic antigen-related cell adhesion molecule 1 in non-small-cell lung cancer.
Zhou MQ; Du Y; Liu YW; Wang YZ; He YQ; Yang CX; Wang WJ; Gao F
BMC Cancer; 2013 Jul; 13():359. PubMed ID: 23885995
[TBL] [Abstract][Full Text] [Related]
54. Serum level of TSGF, CA242 and CA19-9 in pancreatic cancer.
Jiang JT; Wu CP; Deng HF; Lu MY; Wu J; Zhang HY; Sun WH; Ji M
World J Gastroenterol; 2004 Jun; 10(11):1675-7. PubMed ID: 15162550
[TBL] [Abstract][Full Text] [Related]
55. Proposed cut-off value of CA19-9 for detecting pancreatic cancer in patients with diabetes: a case-control study.
Murakami M; Nagai Y; Tenjin A; Tanaka Y
Endocr J; 2018 Jun; 65(6):639-643. PubMed ID: 29643268
[TBL] [Abstract][Full Text] [Related]
56. Up-regulation of carcinoembryonic antigen-related cell adhesion molecule 1 in gastrointestinal cancer and its clinical relevance.
Zhou M; Jin Z; Liu Y; He Y; Du Y; Yang C; Wang Y; Hu J; Cui L; Gao F; Cao M
Acta Biochim Biophys Sin (Shanghai); 2017 Aug; 49(8):737-743. PubMed ID: 28655144
[TBL] [Abstract][Full Text] [Related]
57. Serum DJ-1 as a diagnostic marker and prognostic factor for pancreatic cancer.
He XY; Liu BY; Yao WY; Zhao XJ; Zheng Z; Li JF; Yu BQ; Yuan YZ
J Dig Dis; 2011 Apr; 12(2):131-7. PubMed ID: 21401899
[TBL] [Abstract][Full Text] [Related]
58. CA19-9 and CA242 as tumor markers for the diagnosis of pancreatic cancer: a meta-analysis.
Gui JC; Yan WL; Liu XD
Clin Exp Med; 2014 May; 14(2):225-33. PubMed ID: 23456571
[TBL] [Abstract][Full Text] [Related]
59. Behavior of tumor markers CA19.9, CA195, CAM43, CA242, and TPS in the diagnosis and follow-up of pancreatic cancer.
Banfi G; Zerbi A; Pastori S; Parolini D; Di Carlo V; Bonini P
Clin Chem; 1993 Mar; 39(3):420-3. PubMed ID: 8448851
[TBL] [Abstract][Full Text] [Related]
60. Serum anti-60S ribosomal protein L29 antibody as a novel prognostic marker for unresectable pancreatic cancer.
Muro S; Miyake Y; Kato H; Tsutsumi K; Yamamoto K
Digestion; 2015; 91(2):164-73. PubMed ID: 25765324
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
